Hostname: page-component-7479d7b7d-k7p5g Total loading time: 0 Render date: 2024-07-12T08:04:00.947Z Has data issue: false hasContentIssue false
  • English
  • Français

Platelet Dopamine Uptake in Huntington's Chorea and Gilles de la Tourette's Syndrome: Effect of Haloperidol

Published online by Cambridge University Press:  18 September 2015

Roger F. Butterworth ,
Michel Gonce  and
André Barbeau
Roger F. Butterworth
Affiliation:
Department of Neurology, Clinical Research Institute of Montreal
Michel Gonce
Affiliation:
Department of Neurology, Clinical Research Institute of Montreal
André Barbeau*
Affiliation:
Department of Neurology, Clinical Research Institute of Montreal
*
Department of Neurology, Clinical Research Institute of Montreal, 110 Pine Avenue West, Montreal, Quebec H2W 1R7
Rights & Permissions [Opens in a new window]

Summary:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Uptake of 14C-dopamine by human platelets has been studied in two diseases, namely Gilles de la Tourette's syndrome and Huntington's chorea, in which abnormal metabolism of dopamine has been implicated. Platelets from untreated Huntington's chorea patients showed a small increase in Km and Vmax.; platelets from patients in all other groups showed an uptake identical with the controls. Haloperidol (10 -5M) was also shown to be a strong non-competitive inhibitor of 14C-DA uptake by platelets. This property is probably unrelated to the drugs' action in ameliorating the symptoms of Huntington's chorea which is likely related to the increase in cholinergic neuronal activity produced by neuroleptic blockade of dopamine receptors.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 4 , Issue 4 , November 1977 , pp. 285 - 288
Copyright
Copyright © Canadian Neurological Sciences Federation 1977

References

REFERENCES

Aminoff, M.J., Trenchard, A., Turner, P., Wood, W.G.Hills, M. (1974). Plasma uptake of dopamine and 5-hydroxytry ptamine and plasma catecholamine levels in patients with Huntington’s chorea. Lancet, 1115–1116.CrossRefGoogle Scholar
Barbeau, A. (1973). Biochemistry of Huntington’s chorea. In: Huntington’s chorea 1872–1972. Advances in Neurology. Volume 1, (Barbeau, A., Chase, T.N. and Paulson, G.W., eds.). Raven Press. New York. pp. 473–516.Google Scholar
Barbeau, A. (1975). Maladies du Systéme extrapyramidal. In: Pathologie Médicale (Pequignot, H., ed.). Masson & Cie, Paris, pp. 1446–1453.Google Scholar
Barbeau, A., Campanella, G., Butterworth, R.F. and Yamada, K. (1975). Uptake and Efflux of ’“14C-dopamine by platelets: Evidence for a generalised defect in Parkinson’s disease. Neurol., 25, 1–9.CrossRefGoogle ScholarPubMed
Bird, E.D. and Iversen, L.L. (1974). Huntington’s chorea, post mortem measurement of glutamic acid decarboxylase, choline acetyl transferase and dopamine in basal ganglia. Brain, 97, 457–472.CrossRefGoogle Scholar
Davis, K.L., Hollister, L.E., Barchas, J.D. and Berger, P.A. (1976). Choline in tardive dyskinesia and Huntington’s disease. Life Sciences. 19, 1507–1516.CrossRefGoogle ScholarPubMed
Fog, H. and Pakkenberg, H. (1970). Combined nitroman-pimozide treatment of Huntington’s chorea and other hyperkinetic syndromes. Acta Neurol. Scand., 46, 249–251.CrossRefGoogle ScholarPubMed
Growdon, J.H., Cohen, E.L. and Wurtman, R.J. (1977). Effects of oral choline administration on serum and CSF choline levels in patients with Huntington’s disease. J. Neurochem., 28, 229–231.CrossRefGoogle ScholarPubMed
Horn, A.S., Coyle, J.T. and Snyder, S.H. (1971). Catecholamine uptake by synaptosomes from rat brain. Mol. Pharmacol., 7, 66–80.Google ScholarPubMed
Kehr, W., Carlsson, A., Lindquist, M., Magnusson, T. and Atack, C. (1972). Evidence for a receptor-mediated feedback control of striatal tyrosine hydroxylase activity. J. Pharm. Pharmac, 24, 744–747.CrossRefGoogle ScholarPubMed
Lal, S., De La Vega, C, Garelis, E. and Sourkes, T.L. (1973). Apomorphine, pimozide, L-DOPA and the probenecid test in Huntington’s chorea. Psychiat., Neurol., Neurochir., 76, 113–117.Google ScholarPubMed
Lineweaver, H. and Burk, D. (1934). The determination of enzyme dissociation constants. J. Am. Chem. Soc, 56, 658–666.CrossRefGoogle Scholar
Lott, I.T., Chase, T.N. and Murphy, D.L. (1972). Down’s syndrome: transport, storage and metabolism of serotonin in blood platelets. Pediat. Res., 6, 730–735.CrossRefGoogle ScholarPubMed
Mclean, D.R. and Nihei, I. (1977). Uptake of dopamine and 5-hydroxytryptamine by platelets from patients with Huntington’s chorea. Lancet. 1, 249–250.CrossRefGoogle ScholarPubMed
Murphy, G.F., Mendell, J.R. and Engel, W.K. (1973). Serotonin and platelet function in Duchenne muscular dystrophy. Arch. Neurol., 28. 239–242.CrossRefGoogle ScholarPubMed
Paasonen, M.K. (1973). Blood platelets as a model for aminergic neurons. In: Pharmacology and the Future of Man, Vol. 4. (Karger, S., ed.). Basel, pp. 328–342.Google Scholar
Solomon, H.M., Spirt, N.M. and Abrams, W.B. (1970). The accumulation and metabolism of dopamine by the human platelet. Clin. Pharmacol. Ther., 2. 838–845.CrossRefGoogle Scholar
Stadler, H., Lloyd, K.G., Gadeaciria, M. and Bartholini, G. (1973). Enhanced striatal acetylcholine release by chlorpromazine and its reversal by apomorphine. Brain Res., 55. 476–480.CrossRefGoogle ScholarPubMed